Chronic Myeloid Leukemia Faceoff: UT Southwestern vs Mayo Clinic
Two teams from leading institutions, UT Southwestern and the Mayo Clinic, go head-to-head to review the latest datasets in chronic myeloid leukemia management.
EP. 1: Team Introductions: CML Experts From UT Southwestern vs. Mayo Clinic
Expert panelists from UT Southwestern and the Mayo Clinic introduce themselves and prepare for a team-vs-team debate surrounding recent clinical trial data in chronic myeloid leukemia.
EP. 2: Chronic-Phase CML: The OPTIC Study
Key opinion leader Kebede Begna, MD, reviews data from the OPTIC study focused on ponatinib dosing in chronic-phase CML.
EP. 3: Cross Q&A: Ponatinib Dosing in Relapsed/Refractory Chronic-Phase CML
Expert perspectives from the Mayo Clinic and UT Southwestern teams on applications of the OPTIC study and optimal ponatinib dosing in chronic myeloid leukemia.
EP. 4: Chronic Myeloid Leukemia: Retrospective Analysis of the PACE Study
A focused discussion led by expert Abhishek Mangaonkar, MBBS, on a retrospective analysis elucidating arterial occlusive events within the PACE study.
EP. 5: Cross Q&A: Arterial Occlusive Events With Ponatinib in the PACE Trial
Following a review of the retrospective analysis of PACE, experts reflect on its importance in understanding the risk of arterial occlusive events with ponatinib.
EP. 6: Olverembatinib Study in Patients With Heavily Pretreated Chronic Myeloid Leukemia
A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.
EP. 7: Cross Q&A: Role of Olverembatinib in Heavily Pretreated CML
In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.
EP. 8: Chronic Myeloid Leukemia: Long-Term Follow-up of Low-Dose Dasatinib
In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.
EP. 9: Cross Q&A: Real-World Use of Low-Dose Dasatinib in CML
Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.
